KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Invested Capital (2016 - 2025)

Historic Invested Capital for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $1.9 billion.

  • CRISPR Therapeutics AG's Invested Capital fell 53.14% to $1.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 billion, marking a year-over-year decrease of 53.14%. This contributed to the annual value of $1.9 billion for FY2025, which is 53.14% down from last year.
  • According to the latest figures from Q4 2025, CRISPR Therapeutics AG's Invested Capital is $1.9 billion, which was down 53.14% from $1.9 billion recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Invested Capital ranged from a high of $2.6 billion in Q2 2021 and a low of $1.7 billion during Q2 2025
  • For the 5-year period, CRISPR Therapeutics AG's Invested Capital averaged around $2.0 billion, with its median value being $1.9 billion (2024).
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 18592.08% in 2021, then plummeted by 2224.38% in 2022.
  • Over the past 5 years, CRISPR Therapeutics AG's Invested Capital (Quarter) stood at $2.4 billion in 2021, then decreased by 21.84% to $1.9 billion in 2022, then increased by 0.39% to $1.9 billion in 2023, then grew by 2.62% to $1.9 billion in 2024, then decreased by 0.53% to $1.9 billion in 2025.
  • Its Invested Capital stands at $1.9 billion for Q4 2025, versus $1.9 billion for Q3 2025 and $1.7 billion for Q2 2025.